NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $214,027 | -93.3% | 359,347 | -93.5% | 0.00% | -100.0% |
| Q2 2023 | $3,183,979 | -87.9% | 5,535,430 | -85.2% | 0.00% | -85.7% |
| Q1 2023 | $26,346,510 | -68.8% | 37,482,586 | +0.4% | 0.01% | -72.0% |
| Q4 2022 | $84,360,090 | -29.3% | 37,327,473 | +0.2% | 0.02% | -34.2% |
| Q3 2022 | $119,244,000 | -15.7% | 37,263,645 | +0.1% | 0.04% | -11.6% |
| Q2 2022 | $141,476,000 | -29.5% | 37,230,367 | -0.0% | 0.04% | -15.7% |
| Q1 2022 | $200,672,000 | -59.7% | 37,230,534 | +0.9% | 0.05% | -57.5% |
| Q4 2021 | $498,405,000 | -22.2% | 36,891,494 | +3.4% | 0.12% | -25.9% |
| Q3 2021 | $640,654,000 | +4.7% | 35,671,187 | +0.0% | 0.16% | +8.0% |
| Q2 2021 | $611,897,000 | -13.7% | 35,658,379 | +0.6% | 0.15% | -20.6% |
| Q1 2021 | $708,987,000 | +17.6% | 35,449,394 | -0.0% | 0.19% | +8.0% |
| Q4 2020 | $602,768,000 | +1.8% | 35,456,949 | -0.7% | 0.18% | -12.5% |
| Q3 2020 | $592,117,000 | -22.9% | 35,691,258 | +7.6% | 0.20% | -27.3% |
| Q2 2020 | $768,464,000 | +26.9% | 33,180,644 | -2.2% | 0.28% | +7.8% |
| Q1 2020 | $605,498,000 | -11.3% | 33,921,398 | +7.2% | 0.26% | +20.3% |
| Q4 2019 | $682,714,000 | +8.2% | 31,629,134 | -8.7% | 0.21% | +28.5% |
| Q3 2019 | $631,029,000 | -24.0% | 34,643,386 | +48.4% | 0.16% | -22.9% |
| Q2 2019 | $830,544,000 | +1125.9% | 23,343,019 | +1057.7% | 0.21% | +830.4% |
| Q1 2019 | $67,748,000 | +14.0% | 2,016,288 | +11.6% | 0.02% | 0.0% |
| Q4 2018 | $59,407,000 | -41.9% | 1,807,356 | +7.7% | 0.02% | -28.1% |
| Q3 2018 | $102,258,000 | -1.0% | 1,677,474 | -20.7% | 0.03% | -5.9% |
| Q2 2018 | $103,297,000 | -36.0% | 2,115,415 | +39.3% | 0.03% | -43.3% |
| Q1 2018 | $161,319,000 | +37.9% | 1,518,156 | -22.5% | 0.06% | +42.9% |
| Q4 2017 | $116,958,000 | +34.9% | 1,958,440 | -45.8% | 0.04% | +31.2% |
| Q3 2017 | $86,706,000 | +22.7% | 3,612,747 | -0.0% | 0.03% | +45.5% |
| Q2 2017 | $70,655,000 | -29.3% | 3,614,045 | -15.2% | 0.02% | -33.3% |
| Q1 2017 | $99,993,000 | +83.6% | 4,260,455 | -4.0% | 0.03% | +83.3% |
| Q4 2016 | $54,465,000 | -27.1% | 4,438,815 | +2.1% | 0.02% | -30.8% |
| Q3 2016 | $74,692,000 | +21.4% | 4,347,615 | +0.6% | 0.03% | +13.0% |
| Q2 2016 | $61,515,000 | +1.2% | 4,322,899 | -2.2% | 0.02% | -8.0% |
| Q1 2016 | $60,807,000 | -17.5% | 4,422,402 | +1.1% | 0.02% | -13.8% |
| Q4 2015 | $73,741,000 | +60.3% | 4,376,307 | +4.3% | 0.03% | +45.0% |
| Q3 2015 | $46,005,000 | -8.8% | 4,197,473 | +4.1% | 0.02% | 0.0% |
| Q2 2015 | $50,446,000 | +25.9% | 4,032,435 | +10.7% | 0.02% | +25.0% |
| Q1 2015 | $40,070,000 | -37.5% | 3,642,734 | -11.9% | 0.02% | -36.0% |
| Q4 2014 | $64,087,000 | +188.9% | 4,134,661 | +125.0% | 0.02% | +177.8% |
| Q3 2014 | $22,182,000 | +120.5% | 1,837,754 | +134.2% | 0.01% | +125.0% |
| Q2 2014 | $10,060,000 | -53.2% | 784,678 | -55.8% | 0.00% | -55.6% |
| Q1 2014 | $21,512,000 | +79.2% | 1,774,994 | +67.8% | 0.01% | +80.0% |
| Q4 2013 | $12,005,000 | +69.5% | 1,057,700 | +56.0% | 0.01% | +66.7% |
| Q3 2013 | $7,082,000 | +4590.1% | 678,089 | +5080.2% | 0.00% | – |
| Q2 2013 | $151,000 | – | 13,090 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |